Novel Therapeutics in Acute Myeloid Leukemia

Courtney D. DiNardo; Richard M. Stone; Bruno C. Medeiros

doi:10.14694/EDBK_175401

Novel Therapeutics in Acute Myeloid Leukemia

Courtney D. DiNardo, Richard M. Stone, Bruno C. Medeiros

Leukemia

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

In this review, we focus on three key areas in acute myeloid leukemia (AML) developmental therapeutics: FLT3 inhibitors, IDH inhibitors, and drugs that may be particularly beneficial in secondary AML.

Original language	English (US)
Pages (from-to)	495-503
Number of pages	9
Journal	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Volume	37
DOIs	https://doi.org/10.14694/EDBK_175401
State	Published - 2017

ASJC Scopus subject areas

General Medicine

Access to Document

10.14694/EDBK_175401

Cite this

@article{64e0a7f758074aac8b21fc0e809301f8,

title = "Novel Therapeutics in Acute Myeloid Leukemia",

abstract = "In this review, we focus on three key areas in acute myeloid leukemia (AML) developmental therapeutics: FLT3 inhibitors, IDH inhibitors, and drugs that may be particularly beneficial in secondary AML.",

author = "DiNardo, {Courtney D.} and Stone, {Richard M.} and Medeiros, {Bruno C.}",

year = "2017",

doi = "10.14694/EDBK_175401",

language = "English (US)",

volume = "37",

pages = "495--503",

journal = "American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting",

issn = "1548-8756",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Novel Therapeutics in Acute Myeloid Leukemia

AU - DiNardo, Courtney D.

AU - Stone, Richard M.

AU - Medeiros, Bruno C.

PY - 2017

Y1 - 2017

N2 - In this review, we focus on three key areas in acute myeloid leukemia (AML) developmental therapeutics: FLT3 inhibitors, IDH inhibitors, and drugs that may be particularly beneficial in secondary AML.

AB - In this review, we focus on three key areas in acute myeloid leukemia (AML) developmental therapeutics: FLT3 inhibitors, IDH inhibitors, and drugs that may be particularly beneficial in secondary AML.

UR - http://www.scopus.com/inward/record.url?scp=85043244651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043244651&partnerID=8YFLogxK

U2 - 10.14694/EDBK_175401

DO - 10.14694/EDBK_175401

M3 - Review article

C2 - 28561688

AN - SCOPUS:85043244651

SN - 1548-8756

VL - 37

SP - 495

EP - 503

JO - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

JF - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

ER -

Novel Therapeutics in Acute Myeloid Leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this